Retapamulin: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 30: | Line 30: | ||
'''| [[Retapamulin drug interactions|Drug Interactions]]''' | '''| [[Retapamulin drug interactions|Drug Interactions]]''' | ||
'''| [[Retapamulin overdosage|Overdosage]]''' | '''| [[Retapamulin overdosage|Overdosage]]''' | ||
'''| [[Retapamulin dosage and administration|Dosage and Administration]]''' | '''| [[Retapamulin dosage and administration|Dosage and Administration]]''' | ||
'''| [[Retapamulin how supplied|How Supplied]]''' | '''| [[Retapamulin how supplied|How Supplied]]''' | ||
Revision as of 22:02, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use.
Retapamulin was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. In May 2007, retapamulin received approval in the EU from the European Medicines Agency for the same indication.
Clinical trials have demonstrated its efficacy against certain Gram-positive bacteria including MRSA.[1]
Category
Antibacterial
US Brand Names
ALTABAX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Retapamulin is an antibacterial agent, specifically a protein synthesis inhibitor. The medication selectively inhibits bacterial protein synthesis by interacting at a site on the 50S subunit of the bacterial ribosome through an interaction that differs from other antibiotics.
References
- ↑ Jones R, Fritsche T, Sader H, Ross J (2006). "Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci". Antimicrob Agents Chemother. 50 (7): 2583–6. doi:10.1128/AAC.01432-05. PMC 1489758. PMID 16801451.